Bruton tyrosine kinase (BTK) inhibitors are a class of targeted oral small molecules that have transformed the treatment of B-cell malignancies. They work by blocking a critical survival pathway in malignant B-cells, but their use requires careful management of specific adverse effects and drug interactions .
Mechanism of Action
BTK is a key enzyme in the B-cell receptor (BCR) signaling pathway, which is essential for the proliferation, migration, and survival of normal and malignant B-cells . BTK inhibitors work by blocking this signal, which leads to the death of the malignant B-cells .
- First-Generation (Covalent): Ibrutinib binds irreversibly to the C481 residue of the BTK enzyme, causing strong and continuous inhibition .
- Second-Generation (Covalent): Acalabrutinib and zanubrutinib also bind irreversibly to C481 but were designed for greater selectivity for BTK, minimizing off-target effects .
- Non-Covalent (Reversible): Pirtobrutinib binds reversibly to BTK at a different site, remaining active even in the presence of the C481 mutation that confers resistance to covalent inhibitors .
Generations and Key Examples
| Generation / Type | Drug Name (Examples) | Pharmacy Key Point |
|---|---|---|
| First-Generation (Covalent) | Ibrutinib | The first-in-class; highly effective but has more off-target effects (e.g., higher rates of atrial fibrillation, bleeding, hypertension) due to inhibition of other kinases (TEC, EGFR) . |
| Second-Generation (Covalent) | Acalabrutinib, Zanubrutinib | More selective BTK inhibition. Clinical trials show improved tolerability with lower rates of cardiac events compared to ibrutinib . |
| Non-Covalent (Reversible) | Pirtobrutinib | Novel agent that overcomes C481 mutation-mediated resistance. Active in patients who have progressed on covalent BTK inhibitors . |
FDA-Approved Indications
BTK inhibitors are indicated for a range of B-cell malignancies. Key indications include:
- Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)
- Mantle Cell Lymphoma (MCL)
- Waldenström’s Macroglobulinaemia (WM)
- Marginal Zone Lymphoma (MZL)
Clinical Pearls for the Pharmacist
Your role is critical in monitoring and patient counseling for these key areas:
- Cardiovascular Toxicity: Atrial fibrillation (AF), hypertension, and ventricular arrhythmias are significant risks, particularly with ibrutinib . Second-generation agents have lower, but not zero, cardiac risks .
- Action: Monitor blood pressure regularly. Counsel patients to report palpitations, dizziness, breathlessness, or chest pain .
- Bleeding Risk: BTK inhibitors interfere with platelet function.
- Action: Monitor for bruising, petechiae, or major bleeding . This is particularly important for patients on anticoagulants or antiplatelet agents.
- Infections: There is an increased risk of infections, including respiratory tract infections .
- Action: Monitor for signs of infection. Consider prophylaxis for certain patients as per institutional guidelines.
- Drug-Drug Interactions (DDIs): All covalent BTK inhibitors are primarily metabolized by CYP3A4 .
- Action: Avoid or use caution with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) and inducers (e.g., rifampin, carbamazepine). Dose adjustments are often required with moderate inhibitors.
- Resistance: Acquired resistance to covalent BTK inhibitors often involves a C481 mutation .
- Action: Be aware that pirtobrutinib (non-covalent) is an important therapeutic option for patients who progress on or after a covalent BTK inhibitor
Synonyms
Bruton tyrosine kinase inhibitor